Search
Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14610ApprovedWithdrawnA seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.
Synonyms: Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (formaldehyde inactivated)Indapamide
go.drugbank.com/drugs/DB00808ApprovedInvestigational[A204155] Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. … [A204134,A204161] Indapamide is characterized by both a methylindoline and a sulfamoyl chlorobenzamide functional group, with the former being largely responsible for the molecule’s lipid solubility
Mixtures: Triplixam 10 mg/2,5 mg/10 mg Filmtabletten, COVERATRIX® 10 MG. / 2.5 MG. / 10 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMethenamine
go.drugbank.com/drugs/DB06799ApprovedInvestigationalVet approvedMethenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane.
Mixtures: PURINOL 250 mg+615 mg/5 g EFERVESAN 140 GR, PURINOL 250 mg+615 mg/5 g EFERVESAN 140 GRProducts: NETURONE GRANUL LIBA, 105 G, URON 500 MG TABLET, 21 ADETCarmustine
go.drugbank.com/drugs/DB00262ApprovedInvestigationalA cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: BICNU-100 MG, CARMUSTINA 100 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLETremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigationalCTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).
Products: Imjudo 300 mg/15 ml İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 adet, Imjudo Concentrate for Solution for Intravenous Infusion 20 mg/mLSodium phosphate, monobasic
go.drugbank.com/drugs/DB09449ApprovedInvestigationalSodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.
Mixtures: LAX FOSFOSODA 0.48 G / ML + 0.18 G/ ML ORAL ÇÖZELTİ, 45 ML, NUTRIFLEX LIPID PLUS INFUZYONLUK EMULSIYON, 1250 MLProducts: SODIO FOSFATO LJ PHARMA, BT ORAL SOLUSYON 45 MLSt. John's Wort
go.drugbank.com/drugs/DB01323ApprovedInvestigationalNutraceuticalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InducersProducts: Kira (extract Li 160)Adefovir dipivoxil
go.drugbank.com/drugs/DB00718ApprovedAdefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective ag...
International brands: A Di Xian, A Gan DingProducts: HEPSERA TABLET 10 mg, HEPSERA 10 MG TABLETASBCG vaccine
go.drugbank.com/drugs/DB12768ApprovedInvestigationalWithdrawnBCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
Products: CALGEVAX-BCG 11.25 MG INTRAVEZIKAL ENJEKSIYON IÇIN LIYOFILIZE TOZ IÇEREN AMPUL, 10 ADET, SII-BCG 1 ML ID ENJEKSIYONLUK SUSPANSIYON ICIN LIYOFILIZE TOZ ICEREN COK DOZLU FLAKON, 10 ADETMacitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigationalMacitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013. … A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.
Mixtures: OPSYNVI® (MACITENTAN/TADALAFILO) 10MG/40 MG TABLETAS RECUBIERTASCategories: Endothelin A Receptor Antagonists, Cytochrome P-450 Substrates